View Older Stories View More Recent Stories

Nov 18, 2024 09:00AM Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
Oct 31, 2024 09:00AM Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales
Oct 25, 2024 09:00AM Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
Oct 24, 2024 09:02AM Avalon GloboCare (ALBT) Announces 1:15 Reverse Share Split
Oct 24, 2024 09:00AM Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan
Oct 9, 2024 09:00AM Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device
Aug 14, 2024 08:00AM Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device
Jul 31, 2024 08:00AM Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Jul 18, 2024 09:00AM Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us
Jun 20, 2024 08:30AM Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference
May 24, 2024 05:00PM Avalon GloboCare (ALBT) Receives Nasdaq Non-compliance Notice
May 24, 2024 05:00PM Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
Apr 22, 2024 09:01AM Avalon GloboCare (ALBT) Announces Launch of U.S. Sales of KetoAir Breathalyzer
Apr 22, 2024 09:00AM Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
Mar 28, 2024 09:00AM Avalon GloboCare (ALBT) Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software
Mar 28, 2024 09:00AM Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union
Dec 18, 2023 09:00AM Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US
Oct 18, 2023 09:00AM Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis
Oct 4, 2023 09:00AM Apple Approves Use of Avalon GloboCare’s KetoAir Mobile Application
Sep 13, 2023 09:15AM Avalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device
Sep 5, 2023 08:03AM Avalon GloboCare (ALBT) Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology
Sep 5, 2023 08:00AM Avalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT)
Aug 30, 2023 09:00AM Avalon’s Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis
Aug 21, 2023 09:00AM Avalon’s Laboratory Services MSO Announces Expansion into Arizona
Jul 24, 2023 09:00AM Avalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth
Jul 19, 2023 09:00AM Avalon GloboCare’s Laboratory Services MSO Signs Exclusive In-Network Lab Services Agreement Providing Significant Expansion Opportunity into 21 States
Jul 10, 2023 09:02AM Avalon GloboCare (ALBT) Provides Update on New Commercial Strategy
Jul 10, 2023 09:00AM Avalon GloboCare Provides Update on New Commercial Strategy
Apr 27, 2023 09:00AM Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022
Apr 17, 2023 09:00AM Avalon GloboCare Announces Commercial Launch of KetoAir Breathalyzer at the KetoCon Austin 2023 Conference
Apr 11, 2023 09:00AM Avalon GloboCare Signs Agreement with Qi Diagnostics to Exclusively Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, U.K. and European Union
Mar 3, 2023 09:00AM Avalon GloboCare to Participate in the 35th Annual Roth Conference
Feb 13, 2023 09:05AM Avalon GloboCare (ALBT) Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
Feb 13, 2023 09:00AM Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
Jan 17, 2023 09:00AM Avalon GloboCare (ALBT) Announces U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Jan 17, 2023 09:00AM Avalon GloboCare (ALBT) Announces U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Jan 17, 2023 09:00AM Avalon GloboCare Announces Issuance of Key U.S. Patent for Multiple Novel QTY-Code Modified Cytokine and Chemokine Protein Receptor Molecules
Jan 11, 2023 09:00AM Avalon GloboCare Appoints Lourdes Felix, CEO of a Premier Addiction Treatment Company, to its Board of Directors
Jan 3, 2023 09:00AM Avalon GloboCare Announces the Deployment of Breakthrough Fusion Gene Map Technology
Dec 14, 2022 09:02AM Avalon GloboCare (ALBT) Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market
Dec 14, 2022 09:00AM Avalon GloboCare Announces $4 Million Private Placement of Preferred Stock with the Company’s Chairman which Converts at a Significant Premium to Market; Proceeds to Support Acquisition of Laborator
Dec 12, 2022 09:00AM Avalon GloboCare Continues its U.S. Centric Strategy with a New Proposed Board Composition in Preparation for Acquisition of Laboratory Services MSO, LLC
Nov 9, 2022 04:00PM Avalon GloboCare (AVCO) to Change Ticker to ALBT
Nov 9, 2022 04:00PM Avalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”
View More Recent Stories View Older Stories